Skandinaviska Enskilda Banken AB publ Has $30.04 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Skandinaviska Enskilda Banken AB publ lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 84,005 shares of the biotechnology company's stock after selling 10,768 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.19% of United Therapeutics worth $30,044,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new position in United Therapeutics during the 4th quarter valued at about $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics in the 3rd quarter worth approximately $33,000. MassMutual Private Wealth & Trust FSB increased its holdings in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 58 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after acquiring an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in United Therapeutics in the 4th quarter worth approximately $131,000. Institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

Remove Ads

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the transaction, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $929,678.52. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 116,464 shares of company stock worth $42,396,244. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $1.85 during trading hours on Friday, reaching $307.24. The stock had a trading volume of 494,807 shares, compared to its average volume of 444,109. The stock has a fifty day moving average of $349.77 and a 200 day moving average of $358.54. The stock has a market cap of $13.80 billion, a P/E ratio of 13.49, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same period in the prior year, the company earned $4.36 EPS. On average, equities research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.